EMEA Webinar - Accelerating Drug Discovery with 5D Multiomics and High-Throughput Transcriptomics
Unlock faster, deeper insights in your drug discovery pipeline by utilizing the latest technologies
Date: Wednesday, July 30, 2025
Time: 11:00 AM CEST
In this two-part webinar, you'll explore how AVITI™, AVITI24™ and MERCURIUS™ DRUG-seq enable pharma teams to scale transcriptomics and spatial biology with unprecedented speed, sensitivity, and sample efficiency.
Part 1: 5D Multiomics with AVITI24™
Wilfred Van IJcken, Senior Technical Sales Specialist at Element Biosciences, will introduce AVITI24, the world’s first platform that integrates single cell and spatial detection of RNA, protein, and morphology and next-generation sequencing—all powered by our proprietary avidite base chemistry (ABC). With direct in sample sequencing (DISS) and no library prep, the novel ability of AVITI24 to generate multiomic data from intact samples makes it an ideal solution for teams seeking to reduce experimental complexity while gaining more actionable insights per run. This ultimately leads to deeper insights into disease biology, hit and biomarker identification, and mechanism of action to accelerate discovery.
Part 2: High-Throughput Short-Turnaround Transcriptomics for Compound Screening and Lead Optimization: Scalable, Cost-Effective Insights into MOA and Toxicity
Daniel Alpern, CTO and Co-Founder of Alithea Genomics, will present MERCURIUS™ DRUG-seq: a rapid, scalable solution for transcriptome-wide profiling of compound effects.
By capturing hundreds of treatment conditions per run, MERCURIUS™ DRUG-seq reveals MoA, off-target effects, and early toxicity signature at a fraction of the cost and turnaround time of traditional RNA-seq. Unlike traditional phenotypic or reporter assays, MERCURIUS™ DRUG-seq delivers unbiased, information-rich data that accelerates compound profiling and lead optimization, while remaining highly scalable.
During this presentation, we will showcase how DRUG-seq, combined with the AVITI™ sequencing system from Element Biosciences, enables high-throughput transcriptomic profiling of hundreds of treatment conditions at an unprecedented balance of cost and data quality. You will see how Alithea's integrated workflow enables data generation for 1000+ samples per run and with short turnaround times. In addition, it offers paired-end sequencing of MERCURIUS™ DRUG-seq libraries, enhancing transcript detection and isoform resolution, which is critical to early decision-making.
Join us to learn how AVITI™ and DRUG-seq work better together to transform your discovery pipeline without compromising on data quality.
Speakers:
 | Wilfred van IJcken |
 | Daniel Alpern Co-founder and CTO Alithea Genomics |